Yoshinori Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshinori Matsumoto has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
16 shared publications Yosuke Asano
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
14 shared publicationsTakayuki Katsuyama
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
11 shared publications- Ken-Ei Sada
Department of Clinical Epidemiology, Kochi Medical School, Kochi University , Nankoku
10 shared publications Eri Katsuyama
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
9 shared publicationsShoichi Nawachi
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
8 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1959612
Molecular endotyping in systemic lupus erythematosus: an integrative framework toward precision therapy
Systemic lupus erythematosus (SLE) is a clinically defined syndrome arising from heterogeneous and dynamically interacting molecular programs. Recent transcriptomic, single-cell, spatial, and functional studies have identified recurrent molecular states; however, published three-, five-, six-, and eight-group taxonomies are not directly interchangeable. In this review, the published evidence was synthesized within a pragmatic framework of four overlapping candidate programs: interferon/interferon-stimulated gene (IFN/ISG), B cell/plasmablast, neutrophil/neutrophil extracellular trap (NET), and an emerging immunometabolic program. Complement/immune-complex activation is considered a cross-cutting effector axis rather than a mutually exclusive endotype. The molecular endotype is defined operationally, and a distinction is made between pathway signatures, candidate endotypes, and clinically actionable endotypes. In this review, activity biomarkers, prognostic biomarkers, pharmacodynamic biomarkers, and predictive biomarkers are distinguished; the transcriptomic ISG-high states are distinguished from directly measurable type I IFN bioactivity; and the contributions of short-lived plasmablasts and long-lived plasma cells to autoantibody production are also examined. It should be emphasized that endotype assignment is time- and compartment-dependent and that blood signatures may not fully capture organ-specific disease, particularly lupus nephritis. Molecular endotyping in SLE should therefore be viewed as a research framework toward precision therapy rather than as a current treatment algorithm. Prospective biomarker-enriched trials and longitudinal multi-compartment profiling will be required to establish clinically actionable endotypes.
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1959612
Open AccessMolecular endotyping in systemic lupus erythematosus: an integrative framework toward precision therapy
Systemic lupus erythematosus (SLE) is a clinically defined syndrome arising from heterogeneous and dynamically interacting molecular programs. Recent transcriptomic, single-cell, spatial, and functional studies have identified recurrent molecular states; however, published three-, five-, six-, and eight-group taxonomies are not directly interchangeable. In this review, the published evidence was synthesized within a pragmatic framework of four overlapping candidate programs: interferon/interferon-stimulated gene (IFN/ISG), B cell/plasmablast, neutrophil/neutrophil extracellular trap (NET), and an emerging immunometabolic program. Complement/immune-complex activation is considered a cross-cutting effector axis rather than a mutually exclusive endotype. The molecular endotype is defined operationally, and a distinction is made between pathway signatures, candidate endotypes, and clinically actionable endotypes. In this review, activity biomarkers, prognostic biomarkers, pharmacodynamic biomarkers, and predictive biomarkers are distinguished; the transcriptomic ISG-high states are distinguished from directly measurable type I IFN bioactivity; and the contributions of short-lived plasmablasts and long-lived plasma cells to autoantibody production are also examined. It should be emphasized that endotype assignment is time- and compartment-dependent and that blood signatures may not fully capture organ-specific disease, particularly lupus nephritis. Molecular endotyping in SLE should therefore be viewed as a research framework toward precision therapy rather than as a current treatment algorithm. Prospective biomarker-enriched trials and longitudinal multi-compartment profiling will be required to establish clinically actionable endotypes.
- Open Access
- 1 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1849453
Case Report: sustained five-year remission in eosinophilic granulomatosis with polyangiitis with intestinal perforation after surgery and rituximab-based therapy without glucocorticoid escalation
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis characterized by eosinophilic infiltration and granuloma formation, affecting multiple organs. Gastrointestinal (GI) involvement is relatively uncommon and it typically presents with nonspecific symptoms, such as abdominal pain or diarrhea; in contrast, ulceration and intestinal perforation are rare, but potentially life−threatening complications that often require surgical intervention. The standard treatment for severe GI EGPA includes high−dose glucocorticoids combined with cyclophosphamide or rituximab (RTX). However, the perioperative escalation of glucocorticoids is generally avoided owing to the increased risk of postoperative complications. We report a case with a 5-year follow−up of EGPA resistant to multiple immunosuppressive agents with severe GI involvement, including intestinal perforation and multiple jejunal ulcers, which was successfully treated with RTX for postoperative remission induction and long−term maintenance therapy without any prednisolone escalation. The prednisolone dose was gradually reduced from 17.5 mg/day to 1 mg/day over two years without any escalation, and a sustained remission was achieved throughout the course. This case suggests that RTX may represent a viable therapeutic option for severe or treatment−resistant EGPA in cases with GI involvement when glucocorticoid escalation is undesirable or unsafe, such as in the perioperative setting.
- 1 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1849453
Open AccessCase Report: sustained five-year remission in eosinophilic granulomatosis with polyangiitis with intestinal perforation after surgery and rituximab-based therapy without glucocorticoid escalation
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis characterized by eosinophilic infiltration and granuloma formation, affecting multiple organs. Gastrointestinal (GI) involvement is relatively uncommon and it typically presents with nonspecific symptoms, such as abdominal pain or diarrhea; in contrast, ulceration and intestinal perforation are rare, but potentially life−threatening complications that often require surgical intervention. The standard treatment for severe GI EGPA includes high−dose glucocorticoids combined with cyclophosphamide or rituximab (RTX). However, the perioperative escalation of glucocorticoids is generally avoided owing to the increased risk of postoperative complications. We report a case with a 5-year follow−up of EGPA resistant to multiple immunosuppressive agents with severe GI involvement, including intestinal perforation and multiple jejunal ulcers, which was successfully treated with RTX for postoperative remission induction and long−term maintenance therapy without any prednisolone escalation. The prednisolone dose was gradually reduced from 17.5 mg/day to 1 mg/day over two years without any escalation, and a sustained remission was achieved throughout the course. This case suggests that RTX may represent a viable therapeutic option for severe or treatment−resistant EGPA in cases with GI involvement when glucocorticoid escalation is undesirable or unsafe, such as in the perioperative setting.
- Open Access
- 29 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10 (2)
Sjögren disease and idiopathic inflammatory myopathy overlap presenting as complement-mediated thrombotic microangiopathy/atypical haemolytic uremic syndrome with a complement factor B variant: A case report
Complement-mediated thrombotic microangiopathy (CM-TMA) is often triggered by autoimmune diseases; however, reports of CM-TMA in patients with Sjögren disease and idiopathic inflammatory myopathy are limited. We describe the case of a 48-year-old woman with overlapping Sjögren disease and idiopathic inflammatory myopathy who presented with interstitial lung disease. After the initiation of combination therapy with a calcineurin inhibitor, intravenous cyclophosphamide, and glucocorticoids, she developed progressive thrombocytopenia with schistocytosis, haemolytic anaemia, and acute renal dysfunction. Laboratory testing revealed preserved disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) activity (49%) with negative ADAMTS13 inhibitor and Shiga toxins. Despite therapeutic plasma infusion and plasma exchange, she developed severe cardiac dysfunction and abdominal pain, with progressive haematologic and renal dysfunctions requiring haemodialysis. Based on a clinical diagnosis of CM-TMA, eculizumab was initiated, resulting in gradual improvement in haemolysis markers and platelet counts. However, she developed severe multiorgan complications, including a cerebellar haemorrhage, acute pancreatitis, and coagulopathy, and ultimately died. Genetic testing performed during the clinical course identified a complement factor B p.Arg74His variant. This case represents an instance of CM-TMA associated with a Sjögren disease/idiopathic inflammatory myopathy overlap and a complement factor B variant of uncertain pathogenic significance, suggesting that multiple converging factors may contribute to CM-TMA development.
- 29 June 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 10 (2)
Open AccessSjögren disease and idiopathic inflammatory myopathy overlap presenting as complement-mediated thrombotic microangiopathy/atypical haemolytic uremic syndrome with a complement factor B variant: A case report
Complement-mediated thrombotic microangiopathy (CM-TMA) is often triggered by autoimmune diseases; however, reports of CM-TMA in patients with Sjögren disease and idiopathic inflammatory myopathy are limited. We describe the case of a 48-year-old woman with overlapping Sjögren disease and idiopathic inflammatory myopathy who presented with interstitial lung disease. After the initiation of combination therapy with a calcineurin inhibitor, intravenous cyclophosphamide, and glucocorticoids, she developed progressive thrombocytopenia with schistocytosis, haemolytic anaemia, and acute renal dysfunction. Laboratory testing revealed preserved disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) activity (49%) with negative ADAMTS13 inhibitor and Shiga toxins. Despite therapeutic plasma infusion and plasma exchange, she developed severe cardiac dysfunction and abdominal pain, with progressive haematologic and renal dysfunctions requiring haemodialysis. Based on a clinical diagnosis of CM-TMA, eculizumab was initiated, resulting in gradual improvement in haemolysis markers and platelet counts. However, she developed severe multiorgan complications, including a cerebellar haemorrhage, acute pancreatitis, and coagulopathy, and ultimately died. Genetic testing performed during the clinical course identified a complement factor B p.Arg74His variant. This case represents an instance of CM-TMA associated with a Sjögren disease/idiopathic inflammatory myopathy overlap and a complement factor B variant of uncertain pathogenic significance, suggesting that multiple converging factors may contribute to CM-TMA development.
- 4 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Juvenile‐Onset SAPHO Syndrome With Acne‐Hidradenitis Suppurativa Successfully Treated With Infliximab and Methotrexate
- 4 June 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (8)
Juvenile‐Onset SAPHO Syndrome With Acne‐Hidradenitis Suppurativa Successfully Treated With Infliximab and Methotrexate
- Open Access
Dental infection is associated with early relapse in patients with ANCA-associated vasculitis
Objectives: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV. Methods: This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models. Results: A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections. Conclusions: Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.
Open AccessDental infection is associated with early relapse in patients with ANCA-associated vasculitis
Objectives: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV. Methods: This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models. Results: A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections. Conclusions: Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.
- Open Access
- 15 July 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (14) , 2245-2248
Dyspnea with Hemidiaphragm Elevation in a Patient with Giant Cell Arteritis
We herein report the first case of dyspnea with hemidiaphragm elevation in a 68-year-old woman with active giant cell arteritis (GCA), including successful treatment. Contrast-enhanced computed tomography showed a reduced density of the left ophthalmic artery and the left superficial temporal artery with increased soft tissue compared to the other side, indicating that the GCA had flared up and suggesting that the hemidiaphragm elevation might be caused by vasculitis-associated ischemia of the right phrenic nerve. Hemidiaphragm paralysis due to vasculitis-associated ischemia in patients with GCA needs to be distinguished from local infection, tumors, and hepatomegaly, which are the major causes of hemidiaphragm elevation.
- 15 July 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64 (14) , 2245-2248
Open AccessDyspnea with Hemidiaphragm Elevation in a Patient with Giant Cell Arteritis
We herein report the first case of dyspnea with hemidiaphragm elevation in a 68-year-old woman with active giant cell arteritis (GCA), including successful treatment. Contrast-enhanced computed tomography showed a reduced density of the left ophthalmic artery and the left superficial temporal artery with increased soft tissue compared to the other side, indicating that the GCA had flared up and suggesting that the hemidiaphragm elevation might be caused by vasculitis-associated ischemia of the right phrenic nerve. Hemidiaphragm paralysis due to vasculitis-associated ischemia in patients with GCA needs to be distinguished from local infection, tumors, and hepatomegaly, which are the major causes of hemidiaphragm elevation.
- Open Access
- 11 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1537615
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Poly-ADP-ribosylation (PARylation) is a post-translational modification in which ADP-ribose is added to substrate proteins. PARylation is mediated by a superfamily of ADP-ribosyl transferases known as PARPs and influences a wide range of cellular functions, including genome integrity maintenance, and the regulation of proliferation and differentiation. We and others have recently reported that PARylation of SH3 domain-binding protein 2 (3BP2) plays a role in bone metabolism, immune system regulation, and cytokine production. Additionally, PARylation has recently gained attention as a target for cancer treatment. In this review, we provide an overview of PARylation, its involvement in several signaling pathways related to cancer immunity, and the potential of combination therapies with PARP inhibitors and immune checkpoint inhibitors.
- 11 March 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1537615
Open AccessPARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Poly-ADP-ribosylation (PARylation) is a post-translational modification in which ADP-ribose is added to substrate proteins. PARylation is mediated by a superfamily of ADP-ribosyl transferases known as PARPs and influences a wide range of cellular functions, including genome integrity maintenance, and the regulation of proliferation and differentiation. We and others have recently reported that PARylation of SH3 domain-binding protein 2 (3BP2) plays a role in bone metabolism, immune system regulation, and cytokine production. Additionally, PARylation has recently gained attention as a target for cancer treatment. In this review, we provide an overview of PARylation, its involvement in several signaling pathways related to cancer immunity, and the potential of combination therapies with PARP inhibitors and immune checkpoint inhibitors.
- Open Access
- 14 February 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-5
The first presentation of a case of nail-patella syndrome newly diagnosed at the onset of rheumatoid arthritis: a case report
Nail-patella syndrome (NPS) is a rare autosomal dominant disorder that is characterized by dysplasia of the nails, hypoplasia and/or dislocation of the patella and the presence of iliac horns. Using the CARE guidelines, we present the first reported case of NPS that was newly diagnosed at the onset of rheumatoid arthritis (RA). A 74-year-old man was admitted to our hospital due to an 8-month history of arthralgia in bilateral wrists, elbows and fingers. He had a past history of glaucoma and left patella dislocation that had been operatively recentered at the age of 15 years. Laboratory data showed elevated levels of serum C-reactive protein and rheumatoid factor and an elevated titer of anti-SS-A antibodies, while estimated glomerular filtration rate (eGFR), titers of other antibodies and the results of a urinary test were normal. An X-ray showed deformity of bilateral radial heads and the right elbow, and magnetic resonance imaging (MRI) of his hands showed synovitis and erosion in the multiple swollen joints of the wrists and fingers. In addition to these typical features of RA, he had bilateral thumb nail dysplasia with mild hypoplasia of bilateral patellae and iliac horns as shown by the X-ray. He was diagnosed as having autosomal dominant disorder NPS co-existing with RA and he was treated with methotrexate in combination with an oral Janus kinase (JAK) inhibitor, leading to induction of remission. We have presented a rare case of NPS that was newly diagnosed at the onset of RA. Clinical and radiographic findings of NPS are highlighted in this case report for diagnosing NPS on the basis of typical manifestations.
- 14 February 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-5
Open AccessThe first presentation of a case of nail-patella syndrome newly diagnosed at the onset of rheumatoid arthritis: a case report
Nail-patella syndrome (NPS) is a rare autosomal dominant disorder that is characterized by dysplasia of the nails, hypoplasia and/or dislocation of the patella and the presence of iliac horns. Using the CARE guidelines, we present the first reported case of NPS that was newly diagnosed at the onset of rheumatoid arthritis (RA). A 74-year-old man was admitted to our hospital due to an 8-month history of arthralgia in bilateral wrists, elbows and fingers. He had a past history of glaucoma and left patella dislocation that had been operatively recentered at the age of 15 years. Laboratory data showed elevated levels of serum C-reactive protein and rheumatoid factor and an elevated titer of anti-SS-A antibodies, while estimated glomerular filtration rate (eGFR), titers of other antibodies and the results of a urinary test were normal. An X-ray showed deformity of bilateral radial heads and the right elbow, and magnetic resonance imaging (MRI) of his hands showed synovitis and erosion in the multiple swollen joints of the wrists and fingers. In addition to these typical features of RA, he had bilateral thumb nail dysplasia with mild hypoplasia of bilateral patellae and iliac horns as shown by the X-ray. He was diagnosed as having autosomal dominant disorder NPS co-existing with RA and he was treated with methotrexate in combination with an oral Janus kinase (JAK) inhibitor, leading to induction of remission. We have presented a rare case of NPS that was newly diagnosed at the onset of RA. Clinical and radiographic findings of NPS are highlighted in this case report for diagnosing NPS on the basis of typical manifestations.
- Open Access
- 16 May 2023
- Published by Springer Nature in Research Square
Arthralgia and joint deformity, rheumatoid arthritis? or nail-patella syndrome?
Background: Nail-patella syndrome (NPS) is a rare autosomal dominant systemic disorder that is characterized by dysplasia of the nails, hypoplasia or aplasia of the patella, dislocation of the elbow and the presence of iliac horns. Rheumatoid arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis and subsequent joint destruction. Of note, NPS and RA share some musculoskeletal symptoms such as swan-neck deformities of the fingers and joint dislocation, and renal and neural involvement is also observed in these diseases. The prevalences of NPS and RA are 1/50000 and 1/100-1/200, respectively, while no case of NPS co-existing with RA has been reported. Case presentation: Here, we present the first reported case of nail-patella syndrome co-existing with rheumatoid arthritis. A 74-year-old man who had a past history of glaucoma and elbow dislocation was admitted to our hospital due to an 8-month history of arthralgia in bilateral wrists, elbows and fingers. An X-ray showed deformity of bilateral radial heads and joint space narrowing in the right elbow, and magnetic resonance imaging of his hands showed synovitis and erosion in the multiple swollen joints of the wrists and fingers. In addition to these typical features of rheumatoid arthritis, he had bilateral thumb nail dysplasia with mild hypoplasia of bilateral patella and iliac horns as shown by the X-ray. He was diagnosed as having autosomal dominant disorder nail-patella syndrome co-existing with rheumatoid arthritis and he was treated with methotrexate in combination with an oral Janus kinase (JAK) inhibitor, leading to induction of remission. Conclusions: On the basis of their prevalences, the coexistence of nail-patella syndrome and rheumatoid arthritis with overlapped features, including arthralgia, joint deformity and dislocation, glomerulonephritis and neurological abnormality, could be observed in real-world clinical practice. Since the therapeutic strategy for and the prognosis of these diseases are different, appropriate diagnosis based on clinical and radiographic findings is required to improve future prognosis. (314 words)
- 16 May 2023
- Published by Springer Nature in Research Square
Open AccessArthralgia and joint deformity, rheumatoid arthritis? or nail-patella syndrome?
Background: Nail-patella syndrome (NPS) is a rare autosomal dominant systemic disorder that is characterized by dysplasia of the nails, hypoplasia or aplasia of the patella, dislocation of the elbow and the presence of iliac horns. Rheumatoid arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis and subsequent joint destruction. Of note, NPS and RA share some musculoskeletal symptoms such as swan-neck deformities of the fingers and joint dislocation, and renal and neural involvement is also observed in these diseases. The prevalences of NPS and RA are 1/50000 and 1/100-1/200, respectively, while no case of NPS co-existing with RA has been reported. Case presentation: Here, we present the first reported case of nail-patella syndrome co-existing with rheumatoid arthritis. A 74-year-old man who had a past history of glaucoma and elbow dislocation was admitted to our hospital due to an 8-month history of arthralgia in bilateral wrists, elbows and fingers. An X-ray showed deformity of bilateral radial heads and joint space narrowing in the right elbow, and magnetic resonance imaging of his hands showed synovitis and erosion in the multiple swollen joints of the wrists and fingers. In addition to these typical features of rheumatoid arthritis, he had bilateral thumb nail dysplasia with mild hypoplasia of bilateral patella and iliac horns as shown by the X-ray. He was diagnosed as having autosomal dominant disorder nail-patella syndrome co-existing with rheumatoid arthritis and he was treated with methotrexate in combination with an oral Janus kinase (JAK) inhibitor, leading to induction of remission. Conclusions: On the basis of their prevalences, the coexistence of nail-patella syndrome and rheumatoid arthritis with overlapped features, including arthralgia, joint deformity and dislocation, glomerulonephritis and neurological abnormality, could be observed in real-world clinical practice. Since the therapeutic strategy for and the prognosis of these diseases are different, appropriate diagnosis based on clinical and radiographic findings is required to improve future prognosis. (314 words)